<DOC>
	<DOC>NCT02305355</DOC>
	<brief_summary>Assess efficacy and safety of Omacor® 4g with statin treatment for lowering TG levels in subjects with type 2 Diabetes combined with hyperlipidemia</brief_summary>
	<brief_title>Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>LDLC &lt; 100mg/dL, TG &gt; 150mg/dL, patients on statin treatment for at least 6 weeks prior to randomization. Type 2 Diabetes HbA1c ≤ 10.0 Type 1 Diabetes Patients with PPAR gamma agonist therapy Patients with acute MI, Unstable angina within 6 months History of malignant tumor within 2 years Women with pregnant, breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>